Veracyte, Inc.

204 articles with Veracyte, Inc.

• Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018

  10/15/2018

  Veracyte, Inc. (Nasdaq: VCYT) will release its third quarter 2018 financial results after the close of market on Monday, October 29, 2018

• Veracyte Announces Presentation of “Real World” Clinical Utility Data at CHEST 2018 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis

  10/9/2018

  Preliminary data from ongoing, three-year registry study demonstrate that reduction in potentially harmful invasive procedures extends for first 12 months post-test

• Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis

  10/8/2018

  Veracyte, Inc. (Nasdaq: VCYT) announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

• Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

  10/6/2018

  Study findings reported at the American Thyroid Association Annual Meeting

• Veracyte to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

  9/27/2018

  Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018, at 1:05 p.m. Eastern Time (ET).

• Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

  9/26/2018

  Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

• Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference

  7/30/2018

  Veracyte, Inc. announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 11:30 a.m. Eastern Time in Boston.

• Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock At $10.25 Per Share

  7/26/2018

  Veracyte, Inc. announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $10.25 per share.

• Veracyte Announces Second Quarter 2018 Financial Results

  7/23/2018

  Revenue up 24% to $22.8 Million Compared to Second Quarter 2017

• Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Monday, July 23, 2018

  7/9/2018

  Veracyte, Inc. announced today that it will report its second quarter 2018 financial results after the close of market on Monday, July 23, 2018.

• Veracyte Chairman and CEO to Speak at MedCity CONVERGE

  7/2/2018

  ​Veracyte, Inc. today announced that Bonnie Anderson, chairman and chief executive officer, will speak at the 2018 MedCity CONVERGE conference in a session entitled, “Early Diagnosis Through Predictive Biomarkers, Noninvasive Testing.”

• Veracyte to Present at the William Blair 38th Annual Growth Stock Conference

  5/30/2018

  Veracyte, Inc. announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the William Blair 38th Annual Growth Stock Conference.

• Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis

  5/23/2018

  Veracyte, Inc. announced that clinical validation data published for the first time today – in JAMA Surgery – demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) identifies at least one third more benign thyroid nodules among those deemed indeterminate by cytopathology, as compared to the original, market-leading Afirma test.

• Veracyte to Launch New Afirma Xpression Atlas and Present Platform Performance Data at AACE 2018 Meeting

  5/10/2018

  Multiple Abstracts Showcasing “Real-World” Performance of the Afirma Genomic Sequencing Classifier also to be Presented

• Veracyte Announces First Quarter 2018 Financial Results

  5/1/2018

  Veracyte, Inc. announced financial results for the first quarter ended March 31, 2018 and provided an update on recent business progress.

• Veracyte Announces Precision Medicine Collaboration With Loxo Oncology

  4/11/2018

  Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform

• Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018

  3/19/2018

  Veracyte, Inc. announced that its soon-to-be-launched Afirma Xpression Atlas platform was unveiled at ENDO 2018, the annual meeting of the Endocrine Society, being held March 17-20 in Chicago.

• Veracyte Announces New Data Demonstrating “Real-World” Performance of Afirma GSC To Be Presented at ENDO 2018

  3/14/2018

  Company to Unveil New Afirma Xpression Atlas Platform

• Veracyte Announces Fourth Quarter and Full-Year 2017 Financial Results, Provides 2018 Financial Outlook

  2/27/2018

  Veracyte, Inc. announced financial results and business progress for the quarter and full year ended December 31, 2017, and provided financial guidance for 2018.

• Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018

  2/12/2018

  Following the announcement, Veracyte will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update.